US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Eikon Therapeutics

8.94

-0.2700-2.93%

Post-market: 8.940.00000.00%19:30 EDT

Volume:1.01M

Turnover:9.08M

Market Cap:482.62M

PE:-1.50

High:9.56

Open:9.28

Low:8.79

Close:9.21

52wk High:17.40

52wk Low:7.90

Shares:53.98M

Float Shares:17.65M

Volume Ratio:2.02

T/O Rate:5.72%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-5.9500

EPS(LYR):-115.2900

ROE:-125.02%

ROA:-36.19%

PB:1.03

PE(LYR):-0.08

Loading ...

Overview Company News Filings

Major Investor Makes Bold Move on Eikon Therapeutics Shares

Column Group IV GP Reports Purchase of 89,200 Eikon Therapeutics Shares Valued at $1.03 Million

Eikon Therapeutics Names Ching-Pin Chang as Chief Scientific Officer

Eikon Therapeutics Appoints Ching-Pin Chang, M.d., Ph.d. as Executive Vice President and Chief Scientific Officer

THOMSON REUTERS

Press Release: Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer

Eikon Therapeutics Joins Cantor Global Healthcare Conference Fireside Chat

Eikon Therapeutics to Participate in Investor Conferences in September 2026

Eikon CEO Perlmutter Joins Cantor Fitzgerald KOL Webcast on PARP Inhibitors in Oncology

Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald

Eikon Therapeutics, Inc. (EIKN) Receives a Buy from Morgan Stanley

Eikon Therapeutics Price Target Cut to $4.00/Share from $5.00 by Wedbush

Eikon Therapeutics Highlights Q3 2026 Oncology Pipeline Progress

Eikon Therapeutics Q2 EPS $(1.63) Misses $(1.54) Estimate

Benzinga Earnings

Eikon Net Loss Narrows 16% to $88.4 Million in Q2 FY26; R&D Expenses Rise 9% to $75.5 Million

Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

Eikon Selects 0.6 Mg/m2 Dose for Eik1001 in TeLuRide-006 Advanced Melanoma Trial

Eikon Therapeutics - DMC Recommends Teluride-006 Study Continue as Planned

THOMSON REUTERS

Eikon Therapeutics Announces Dose Selection for Teluride-006, an Ongoing Adaptive Phase 2/3 Trial of Eik1001 in Advanced Melanoma

THOMSON REUTERS

Eikon Therapeutics Appoints Johnny Bennett, Ph.d. to Its Scientific Advisory Board

THOMSON REUTERS

Press Release: Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to Its Scientific Advisory Board

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/stock/EIKN/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"EIKN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EIKN\",,,,,undefined,":{"symbol":"EIKN","market":"US","secType":"STK","nameCN":"Eikon Therapeutics","latestPrice":8.94,"timestamp":1789156800000,"preClose":9.21,"halted":0,"volume":1010238,"hourTrading":{"tag":"盘后","latestPrice":8.94,"preClose":8.94,"latestTime":"19:30 EDT","volume":15,"amount":134.16,"timestamp":1789169408186,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.029315960912052262,"floatShares":17648000,"shares":53984300,"eps":-5.95,"marketStatus":"Market Closed","change":-0.27,"latestTime":"09-11 16:00:00 EDT","open":9.28,"high":9.56,"low":8.79,"amount":9076866.696321,"amplitude":0.083605,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-5.95,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"listingDate":1770267600000,"exchange":"NASDAQ","adjPreClose":9.21,"preHourTrading":{"tag":"盘前","latestPrice":9.1759,"preClose":9.21,"latestTime":"07:03 EDT","volume":251,"amount":2303.355214,"timestamp":1789124637568,"change":-0.0341,"changeRate":-0.003702,"amplitude":0.022161},"postHourTrading":{"tag":"盘后","latestPrice":8.94,"preClose":8.94,"latestTime":"19:30 EDT","volume":15,"amount":134.16,"timestamp":1789169408186,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.016145},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EIKN\",,,,,undefined,":{"symbol":"EIKN","floatShares":17648000,"roa":"-36.19%","roe":"-125.02%","lyrEps":-115.29,"volumeRatio":2.016145,"shares":53984300,"dividePrice":0,"high":9.56,"amplitude":0.083605,"preClose":9.21,"low":8.79,"week52Low":7.9,"pbRate":"1.03","week52High":17.4,"institutionHeld":0,"latestPrice":8.94,"eps":-5.95,"divideRate":0,"volume":1010238,"delay":0,"ttmEps":-5.95,"open":9.28,"prevYearClose":18,"prevWeekClose":10.86,"prevMonthClose":10.46,"prevQuarterClose":13.05,"fiveDayClose":10.96,"twentyDayClose":10.33,"sixtyDayClose":9.07},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EIKN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"EIKN","fiscalQuarterEnding":"2026/06","expectedEps":-1.61,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"post","actualEps":-1.63},{"market":"US","date":"2026-05-11","symbol":"EIKN","fiscalQuarterEnding":"2026/03","expectedEps":-1.47,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778472000000,"reportTimeType":"post","actualEps":-2.46}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EIKN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EIKN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1667,"buy":0.6667,"hold":0,"sell":0,"strongSell":0.1667,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1774929600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EIKN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EIKN","date":"2026-09-10","current":-1.502521,"percent":0.459459,"low":-3.139466,"twenty":-2.084284,"median":-1.761474,"eighty":-1.536491,"high":-1.335246,"avg":-1.861226,"sd":0.376024,"marketCap":581190771},"quantilePoints":[{"date":"2026-02-06","current":-2.616222,"twenty":-3.034817,"median":-2.877844,"eighty":-2.720871,"marketCap":809765055},{"date":"2026-02-13","current":-2.586571,"twenty":-2.610292,"median":-2.537735,"eighty":-2.527619,"marketCap":800587717},{"date":"2026-02-20","current":-2.703429,"twenty":-2.7418,"median":-2.616222,"eighty":-2.529014,"marketCap":836757223},{"date":"2026-02-27","current":-2.379017,"twenty":-2.703429,"median":-2.596164,"eighty":-2.52727,"marketCap":736346356},{"date":"2026-03-06","current":-2.535991,"twenty":-2.644128,"median":-2.595292,"eighty":-2.523782,"marketCap":784932259},{"date":"2026-03-13","current":-2.054606,"twenty":-2.624942,"median":-2.562153,"eighty":-2.406924,"marketCap":635935489},{"date":"2026-03-20","current":-1.915074,"twenty":-2.616222,"median":-2.529014,"eighty":-2.298787,"marketCap":592748020},{"date":"2026-03-27","current":-1.836588,"twenty":-2.600524,"median":-2.515933,"eighty":-2.054606,"marketCap":568455068},{"date":"2026-04-02","current":-1.678228,"twenty":-2.599129,"median":-2.426109,"eighty":-1.985189,"marketCap":544162116},{"date":"2026-04-10","current":-1.504368,"twenty":-2.597385,"median":-2.379017,"eighty":-1.821565,"marketCap":487788380},{"date":"2026-04-17","current":-1.876704,"twenty":-2.595641,"median":-2.269137,"eighty":-1.751381,"marketCap":608517358},{"date":"2026-04-24","current":-1.786542,"twenty":-2.595292,"median":-2.061583,"eighty":-1.769507,"marketCap":579282538},{"date":"2026-05-01","current":-1.605383,"twenty":-2.588315,"median":-2.045013,"eighty":-1.651966,"marketCap":520542206},{"date":"2026-05-08","current":-1.531083,"twenty":-2.547502,"median":-1.986901,"eighty":-1.641614,"marketCap":496450549},{"date":"2026-05-15","current":-2.105086,"twenty":-2.53634,"median":-1.963159,"eighty":-1.651966,"marketCap":713546154},{"date":"2026-05-22","current":-1.782455,"twenty":-2.530409,"median":-1.936811,"eighty":-1.659647,"marketCap":604186273},{"date":"2026-05-29","current":-1.645097,"twenty":-2.527968,"median":-1.929027,"eighty":-1.650964,"marketCap":557627116},{"date":"2026-06-05","current":-1.562046,"twenty":-2.525177,"median":-1.895889,"eighty":-1.633553,"marketCap":529475781},{"date":"2026-06-12","current":-1.360801,"twenty":-2.514363,"median":-1.841551,"eighty":-1.597703,"marketCap":461261110},{"date":"2026-06-18","current":-1.55406,"twenty":-2.482968,"median":-1.809917,"eighty":-1.567693,"marketCap":526768850},{"date":"2026-06-26","current":-1.573226,"twenty":-2.429947,"median":-1.776985,"eighty":-1.53713,"marketCap":533265485},{"date":"2026-07-02","current":-1.95655,"twenty":-2.406226,"median":-1.79823,"eighty":-1.541282,"marketCap":663198193},{"date":"2026-07-10","current":-1.79204,"twenty":-2.398552,"median":-1.809917,"eighty":-1.555657,"marketCap":607435406},{"date":"2026-07-17","current":-1.589198,"twenty":-2.377273,"median":-1.784498,"eighty":-1.563963,"marketCap":538679348},{"date":"2026-07-24","current":-1.536491,"twenty":-2.355995,"median":-1.761474,"eighty":-1.543838,"marketCap":520813601},{"date":"2026-07-31","current":-1.536491,"twenty":-2.298787,"median":-1.731347,"eighty":-1.536491,"marketCap":520813601},{"date":"2026-08-07","current":-1.471006,"twenty":-2.239486,"median":-1.715581,"eighty":-1.534894,"marketCap":498616763},{"date":"2026-08-14","current":-1.736786,"twenty":-2.116266,"median":-1.712181,"eighty":-1.534894,"marketCap":559524759},{"date":"2026-08-21","current":-1.807401,"twenty":-2.105086,"median":-1.719889,"eighty":-1.534894,"marketCap":582274072},{"date":"2026-08-28","current":-1.936861,"twenty":-2.105086,"median":-1.736786,"eighty":-1.536491,"marketCap":623981145},{"date":"2026-09-04","current":-1.842708,"twenty":-2.084325,"median":-1.759483,"eighty":-1.536491,"marketCap":593648728},{"date":"2026-09-10","current":-1.804038,"twenty":-2.084284,"median":-1.761474,"eighty":-1.536491,"marketCap":581190771}],"updateTime":1789193637596},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EIKN\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666730998","title":"Major Investor Makes Bold Move on Eikon Therapeutics Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2666730998","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666730998?lang=en_us&edition=fundamental","pubTime":"2026-09-09 10:06","pubTimestamp":1788919582,"startTime":"0","endTime":"0","summary":"New insider activity at Eikon Therapeutics, Inc. ( ($EIKN) ) has taken place on September 8, 2026. Significant shareholder Column Group GP IV LP ha...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/major-investor-makes-bold-move-on-eikon-therapeutics-shares-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/major-investor-makes-bold-move-on-eikon-therapeutics-shares-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666637712","title":"Column Group IV GP Reports Purchase of 89,200 Eikon Therapeutics Shares Valued at $1.03 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2666637712","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666637712?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:34","pubTimestamp":1788899655,"startTime":"0","endTime":"0","summary":"Column Group IV GP reports purchase of 89,200 Eikon Therapeutics shares valued at $1.03 millionColumn Group IV GP reported a purchase of 89,200 Eikon Therapeutics common shares at USD 11.56.Indirect holdings reported at 4,312,139 shares via Column Group IV, 1,319,164 via Column Group Opportunity III, 148,840 via Column Group IV-A.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eikon Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 08, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL9sNLXZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Column Group IV GP Reports Purchase of 89,200 Eikon Therapeutics Shares Valued at $1.03 Million","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664487978","title":"Eikon Therapeutics Names Ching-Pin Chang as Chief Scientific Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2664487978","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664487978?lang=en_us&edition=fundamental","pubTime":"2026-09-03 19:32","pubTimestamp":1788435147,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics names Ching-Pin Chang as chief scientific officerEikon Therapeutics named Ching-Pin “CP” Chang executive vice president, chief scientific officer.Chang joins from Bristol Myers Squi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL9l9Cns:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IHE","LU2242652126.USD","IE00BQXX3D17.EUR","IE00B64PRP62.GBP","BK4550","LU0114720955.EUR","IBB","LU2125154778.USD","LU2089984988.USD","LU2095319765.USD","TBXU","FTXH","IBBQ","BBH","LU1839511570.USD","LU0306807586.USD","LU0321505868.SGD","NDAQ","LU1057294990.SGD","MEDI","LU2133065610.SGD","BMED","GILD","LU1934455194.USD","EIKN","LU1291159041.SGD","TMED","LU0109394709.USD","BCDF","LU2087621335.USD","BIB","BMY","LU0122379950.USD","LU2242646821.SGD","LU0965509010.AUD","LU2360032135.SGD","LU1023059063.AUD","LU1236620834.HKD","BK4585","LU1585245621.USD","LU1093756325.SGD","IE00BKPKM429.USD","IE00BQXX3C00.GBP","LU1718418525.SGD","IE00BN0W2V16.EUR","SG9999014021.USD","LU0859254822.USD","LU1983299246.USD","LU1093756168.USD","LU0267386448.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664887923","title":"Eikon Therapeutics Appoints Ching-Pin Chang, M.d., Ph.d. as Executive Vice President and Chief Scientific Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2664887923","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664887923?lang=en_us&edition=fundamental","pubTime":"2026-09-03 19:30","pubTimestamp":1788435001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nTUA3N4SRT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664781879","title":"Press Release: Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2664781879","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664781879?lang=en_us&edition=fundamental","pubTime":"2026-09-03 19:30","pubTimestamp":1788435000,"startTime":"0","endTime":"0","summary":"MILLBRAE, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (\"Eikon\"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662715602","title":"Eikon Therapeutics Joins Cantor Global Healthcare Conference Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2662715602","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662715602?lang=en_us&edition=fundamental","pubTime":"2026-08-26 19:31","pubTimestamp":1787743864,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics joins Cantor Global Healthcare Conference fireside chatEikon Therapeutics will join the 12th Annual Cantor Global Healthcare Conference in New York on Sept. 10, 2026 at 2:10 p.m. ET","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDLVTLCl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0795875169.SGD","LU0267386448.USD","BK4516","LU1244550494.USD","LU2028103732.USD","IE00BN0W2T93.GBP","LU1791710400.SGD","LU0557290698.USD","IE00BQXX3C00.GBP","IE00B3QW5Z07.USD","BK4112","LU0158827948.USD","LU2095319765.USD","LU0795875086.SGD","BK4588","LU0314104364.USD","LU0106261372.USD","IE00BKVL7J92.USD","LU0390134368.USD","EIKN","IE00BZ1G4Q59.USD","LU2487616109.SGD","SG9999014039.USD","LU0912757837.SGD","LU1720051108.HKD","LU0882574139.USD","LU0971096721.USD","BCDF","LU0210528500.USD","LU1363072403.SGD","LU1064131342.USD","BK4139","BK4534","BK4127","IE00BGHQF748.EUR","BK4581","LU1720051017.SGD","LU1732799900.SGD","LU2271345857.HKD","LU1244550221.USD","LU1074936037.SGD","NDAQ","LU0320765646.SGD","KBWB","IAI","LU2133065610.SGD","IE00BN0W2W23.USD","SG9999014005.SGD","LU2089283258.USD","LU0098860793.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662157667","title":"Eikon Therapeutics to Participate in Investor Conferences in September 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2662157667","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662157667?lang=en_us&edition=fundamental","pubTime":"2026-08-26 19:30","pubTimestamp":1787743800,"startTime":"0","endTime":"0","summary":"MILLBRAE, Calif., Aug.  26, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/26/3351236/0/en/eikon-therapeutics-to-participate-in-investor-conferences-in-september-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660449477","title":"Eikon CEO Perlmutter Joins Cantor Fitzgerald KOL Webcast on PARP Inhibitors in Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2660449477","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660449477?lang=en_us&edition=fundamental","pubTime":"2026-08-19 04:15","pubTimestamp":1787084118,"startTime":"0","endTime":"0","summary":"Eikon CEO Perlmutter joins Cantor Fitzgerald KOL webcast on PARP inhibitors in oncologyEikon Therapeutics will join a Cantor Fitzgerald-hosted KOL event on Aug. 20, 2026 at 9:00 a.m. ET.Chairman and C","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDLQxCq8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","IE00B64PRP62.GBP","LU2095319765.USD","SG9999014005.SGD","LU0314104364.USD","BK4139","BK4112","IE00BN0W2W23.USD","IE00BQXX3D17.EUR","NDAQ","IE00BQXX3C00.GBP","SG9999014039.USD","SG9999014013.SGD","IE00BN0W2T93.GBP","BK4588","IE00BGHQF748.EUR","LU2210150020.SGD","SG9999014021.USD","BK4585","IE00BKPKM429.USD","EIKN","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","IE00BQXX3F31.USD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660929014","title":"Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2660929014","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660929014?lang=en_us&edition=fundamental","pubTime":"2026-08-19 04:15","pubTimestamp":1787084100,"startTime":"0","endTime":"0","summary":"Event and Webcast to be held August 20th, 2026, 9:00 AM ETMILLBRAE, Calif., Aug.  18, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutica","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/18/3347241/0/en/eikon-therapeutics-to-participate-in-kol-event-on-therapeutic-use-of-parp-inhibitors-in-oncology-hosted-by-cantor-fitzgerald.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KOL","EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660480036","title":"Eikon Therapeutics, Inc. (EIKN) Receives a Buy from Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2660480036","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660480036?lang=en_us&edition=fundamental","pubTime":"2026-08-17 20:58","pubTimestamp":1786971506,"startTime":"0","endTime":"0","summary":"In a report released today, Sean Laaman from Morgan Stanley maintained a Buy rating on Eikon Therapeutics, Inc., with a price target of $32.00. Laa...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/eikon-therapeutics-inc-eikn-receives-a-buy-from-morgan-stanley-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/eikon-therapeutics-inc-eikn-receives-a-buy-from-morgan-stanley-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659144099","title":"Eikon Therapeutics Price Target Cut to $4.00/Share from $5.00 by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2659144099","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659144099?lang=en_us&edition=fundamental","pubTime":"2026-08-14 21:29","pubTimestamp":1786714140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EIKN/analyst-ratings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659433021","title":"Eikon Therapeutics Highlights Q3 2026 Oncology Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2659433021","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659433021?lang=en_us&edition=fundamental","pubTime":"2026-08-14 18:35","pubTimestamp":1786703738,"startTime":"0","endTime":"0","summary":"An update from Eikon Therapeutics, Inc. ( ($EIKN) ) is now available. On August 13, 2026, Eikon Therapeutics, Inc. updated its corporate presentati...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eikon-therapeutics-highlights-q3-2026-oncology-pipeline-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eikon-therapeutics-highlights-q3-2026-oncology-pipeline-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRGS","LU2065732104.USD","EIKN","BK4097","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659167560","title":"Eikon Therapeutics Q2 EPS $(1.63) Misses $(1.54) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2659167560","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659167560?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:21","pubTimestamp":1786652519,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics Q2 EPS $(1.63) Misses $(1.54) Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/quote/EIKN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Eikon Therapeutics Q2 EPS $(1.63) Misses $(1.54) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659628611","title":"Eikon Net Loss Narrows 16% to $88.4 Million in Q2 FY26; R&D Expenses Rise 9% to $75.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659628611","media":"Reuters","labels":["executive","dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659628611?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:04","pubTimestamp":1786651485,"startTime":"0","endTime":"0","summary":"Eikon net loss narrows 16% to $88.4 million in Q2 FY26; R&D expenses rise 9% to $75.5 millionEikon reported Q2 2026 net loss attributable to common stockholders narrowed to USD 88.4 million from USD 1","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL3wk4Rj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","SG9999014013.SGD","IE00BGHQF748.EUR","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00BKPKM429.USD","BCDF","IE00BN0W2T93.GBP","LU2210150020.SGD","BK4585","EIKN","BK4112","IE00B64PRP62.GBP","LU2095319765.USD","NDAQ","SG9999014039.USD","IE00BN0W2V16.EUR","LU0314104364.USD","BK4139","SG9999014005.SGD","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659516286","title":"Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2659516286","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659516286?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:02","pubTimestamp":1786651320,"startTime":"0","endTime":"0","summary":"Eikon announced seven abstracts accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026 highlighting progress across Eikon’s oncology portfolio, including clinical ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/13/3344893/0/en/eikon-therapeutics-reports-second-quarter-2026-financial-results-and-provides-clinical-updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4135","BK4139","LU0210528500.USD","BK4107","LU2487616109.SGD","L","BK4585","DMC","CNS","LU0053666078.USD","BK4189","EIKN","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658846997","title":"Eikon Selects 0.6 Mg/m2 Dose for Eik1001 in TeLuRide-006 Advanced Melanoma Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2658846997","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658846997?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:31","pubTimestamp":1786447894,"startTime":"0","endTime":"0","summary":"Eikon selects 0.6 mg/m2 dose for EIK1001 in TeLuRide-006 advanced melanoma trialEikon Therapeutics selected a 0.60 mg/m2 dose for EIK1001 in the ongoing TeLuRide-006 adaptive Phase 2/3 trial in advanc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL2gfygh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2210149790.SGD","EIKN","LU0314104364.USD","BK4112","BK4585","IE00BN0W2V16.EUR","BK4139","IE00B64PRP62.GBP","BCDF","SG9999014013.SGD","IE00BN0W2T93.GBP","SG9999014005.SGD","LU2210150020.SGD","IE00B3QW5Z07.USD","NDAQ","IE00BN0W2W23.USD","SG9999014039.USD","IE00BGHQF748.EUR","SG9999014021.USD","IE00BKPKM429.USD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658992063","title":"Eikon Therapeutics - DMC Recommends Teluride-006 Study Continue as Planned","url":"https://stock-news.laohu8.com/highlight/detail?id=2658992063","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658992063?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:30","pubTimestamp":1786447800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nTUAB5KLWN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658992060","title":"Eikon Therapeutics Announces Dose Selection for Teluride-006, an Ongoing Adaptive Phase 2/3 Trial of Eik1001 in Advanced Melanoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2658992060","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658992060?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:30","pubTimestamp":1786447800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nTUAB5KLWN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658336339","title":"Eikon Therapeutics Appoints Johnny Bennett, Ph.d. to Its Scientific Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2658336339","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658336339?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:30","pubTimestamp":1786361401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nTUAQBMQL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658933604","title":"Press Release: Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to Its Scientific Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2658933604","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658933604?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:30","pubTimestamp":1786361400,"startTime":"0","endTime":"0","summary":"MILLBRAE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (\"Eikon\"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":54,"code":"91000000","status":"200"}]}}